ginsenoside rk3 profile

ginsenoside Rk3: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	75412555
CHEMBL ID	4215641
SCHEMBL ID	18542864
MeSH ID	M0446936

Synonym
CS-3848
ginsenoside rk3
364779-15-7
HY-N0906
AKOS030526797
AC-34682
SCHEMBL18542864
mfcd23379928
(2r,3r,4s,5s,6r)-2-[[(3s,5r,6s,8r,9r,10r,12r,13r,14r,17s)-3,12-dihydroxy-4,4,8,10,14-pentamethyl-17-(6-methylhepta-1,5-dien-2-yl)-2,3,5,6,7,9,11,12,13,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-6-yl]oxy]-6-(hydroxymethyl)oxane-3,4,5-triol
CHEMBL4215641
AS-78397

Excerpt	Reference	Relevance
"Ginsenoside Rk3 is a natural prebiotic found in ginseng, has excellent pharmacological efficacy, especially antitumor effects, and can greatly benefit human health. "	( Ginsenoside Rk3 alleviates gut microbiota dysbiosis and colonic inflammation in antibiotic-treated mice. Bai, X; Duan, Z; Fan, D; Fu, R; Wang, P; Zhu, C, 2021)	3.51
"Ginsenoside Rk3 (G-Rk3) is a main active ingredient of ginsenosides. "	( Ginsenoside Rk3 ameliorates high-fat-diet/streptozocin induced type 2 diabetes mellitus in mice via the AMPK/Akt signaling pathway. Deng, J; Fan, D; Liu, Y, 2019)	3.4

Excerpt	Reference	Relevance
" The pharmacokinetic profiles of Rh4 and Rk3 were subsequently assessed in Sprague-Dawley rats."	( Quantification of ginsenosides Rh4 and Rk3 in rat plasma by liquid chromatography-tandem mass spectrometry: application to a pre-clinical pharmacokinetic study. Koh, HL; Lin, HS; Patel, DN, 2012)	0.38

Excerpt	Reference	Relevance
" Similar to many other ginsenosides, the oral bioavailability of Rh4 and Rk3 was unfavorable, and Rh4 and Rk3 did not have any measurable plasma exposure after oral administration (20 mg/kg)."	( Quantification of ginsenosides Rh4 and Rk3 in rat plasma by liquid chromatography-tandem mass spectrometry: application to a pre-clinical pharmacokinetic study. Koh, HL; Lin, HS; Patel, DN, 2012)	0.38

Assay ID	Title	Year	Journal	Article
AID1370961	Activation of SIRT1 (unknown origin) assessed as Fluor de Lys deacetylation at 10 to 20 uM incubated for 5 mins followed by substrate addition measured after 45 mins in presence of NAD/NADH by fluorescence assay	2018	Bioorganic & medicinal chemistry letters, 02-01, Volume: 28, Issue:3	SIRT1 activator isolated from artificial gastric juice incubate of total saponins in stems and leaves of Panax ginseng.
AID1370960	Inhibition of SIRT1 (unknown origin) assessed as reduction in Fluor de Lys deacetylation at 10 to 20 uM incubated for 5 mins followed by substrate addition measured after 45 mins in presence of NAD/NADH by fluorescence assay	2018	Bioorganic & medicinal chemistry letters, 02-01, Volume: 28, Issue:3	SIRT1 activator isolated from artificial gastric juice incubate of total saponins in stems and leaves of Panax ginseng.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (6.25)	29.6817
2010's	9 (56.25)	24.3611
2020's	6 (37.50)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	16 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
niacinamide nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.	2.17	1	pyridine alkaloid; pyridinecarboxamide; vitamin B3	anti-inflammatory agent; antioxidant; cofactor; EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor; EC 3.5.1.98 (histone deacetylase) inhibitor; Escherichia coli metabolite; geroprotector; human urinary metabolite; metabolite; mouse metabolite; neuroprotective agent; Saccharomyces cerevisiae metabolite; Sir2 inhibitor
acetaminophen Acetaminophen: Analgesic antipyretic derivative of acetanilide. It has weak anti-inflammatory properties and is used as a common analgesic, but may cause liver, blood cell, and kidney damage.. paracetamol : A member of the class of phenols that is 4-aminophenol in which one of the hydrogens attached to the amino group has been replaced by an acetyl group.	7.31	1	acetamides; phenols	antipyretic; cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor; cyclooxygenase 3 inhibitor; environmental contaminant; ferroptosis inducer; geroprotector; hepatotoxic agent; human blood serum metabolite; non-narcotic analgesic; non-steroidal anti-inflammatory drug; xenobiotic
chloroquine Chloroquine: The prototypical antimalarial agent with a mechanism that is not well understood. It has also been used to treat rheumatoid arthritis, systemic lupus erythematosus, and in the systemic therapy of amebic liver abscesses.. chloroquine : An aminoquinoline that is quinoline which is substituted at position 4 by a [5-(diethylamino)pentan-2-yl]amino group at at position 7 by chlorine. It is used for the treatment of malaria, hepatic amoebiasis, lupus erythematosus, light-sensitive skin eruptions, and rheumatoid arthritis.	2.31	1	aminoquinoline; organochlorine compound; secondary amino compound; tertiary amino compound	anticoronaviral agent; antimalarial; antirheumatic drug; autophagy inhibitor; dermatologic drug
ribavirin Rebetron: Rebetron is tradename	7.17	1	1-ribosyltriazole; aromatic amide; monocarboxylic acid amide; primary carboxamide	anticoronaviral agent; antiinfective agent; antimetabolite; antiviral agent; EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor
ginsenoside rh2 ginsenoside Rh2: from leaves of Panax ginseng C; structure given in first source. (20S)-ginsenoside Rh2 : A ginsenoside found in Panax species that is dammarane which is substituted by hydroxy groups at the 3beta, 12beta and 20 pro-S positions, in which the hydroxy group at position 3 has been converted to the corresponding beta-D-glucopyranoside, and in which a double bond has been introduced at the 24-25 position.	2.17	1	12beta-hydroxy steroid; 20-hydroxy steroid; beta-D-glucoside; ginsenoside; tetracyclic triterpenoid	antineoplastic agent; apoptosis inducer; bone density conservation agent; cardioprotective agent; hepatoprotective agent; plant metabolite
resveratrol trans-resveratrol : A resveratrol in which the double bond has E configuration.	2.17	1	resveratrol	antioxidant; phytoalexin; plant metabolite; quorum sensing inhibitor; radical scavenger
ginsenosides ginsenoside : Triterpenoid saponins with a dammarane-like skeleton originally isolated from ginseng (Panax) species. Use of the term has been extended to include semi-synthetic derivatives.	4.08	13
ginsenoside f1 ginsenoside F1: from ginseng. ginsenoside F1 : A ginsenoside found in Panax species that is dammarane which is substituted by hydroxy groups at the 3beta, 6alpha, 12beta and 20 pro-S positions, in which the hydroxy group at position 20 has been converted to the corresponding beta-D-glucopyranoside, and in which a double bond has been introduced at the 24-25 position.	2.17	1	12beta-hydroxy steroid; 3beta-hydroxy-4,4-dimethylsteroid; 3beta-hydroxy steroid; 6alpha-hydroxy steroid; beta-D-glucoside; ginsenoside; tetracyclic triterpenoid	apoptosis inhibitor; plant metabolite
ginsenoside rg3 ginsenoside Rg3: from Red ginseng; inhibits lung metastasis of tumor cells; structure given in first source. (20S)-ginsenoside Rg3 : A ginsenoside found in Panax ginseng and Panax japonicus var. major that is dammarane which is substituted by hydroxy groups at the 3beta, 12beta and 20 pro-S positions, in which the hydroxy group at position 3 has been converted to the corresponding beta-D-glucopyranosyl-beta-D-glucopyranoside, and in which a double bond has been introduced at the 24-25 position.	2.17	1	ginsenoside; glycoside; tetracyclic triterpenoid	angiogenesis modulating agent; antineoplastic agent; apoptosis inducer; plant metabolite
protopanaxadiol, (3beta,12beta)-isomer (20S)-protopanaxadiol : A diastereomer of protopanaxadiol in which the 20-hydroxy substituent has been introduced at the pro-S position.	2.17	1	protopanaxadiol
ginsenoside rk1 ginsenoside Rk1: structure in first source	2.01	1
cytochrome c-t Cytochromes c: Cytochromes of the c type that are found in eukaryotic MITOCHONDRIA. They serve as redox intermediates that accept electrons from MITOCHONDRIAL ELECTRON TRANSPORT COMPLEX III and transfer them to MITOCHONDRIAL ELECTRON TRANSPORT COMPLEX IV.	2.15	1
ginsenoside rg2 ginsenoside Rg2: structure in first source; RN given refers to (6-deoxy-alpha-L-mannopyranosyl)-isomer. ginsenoside Rg2 : A ginsenoside found in Panax species that is dammarane which is substituted by hydroxy groups at the 3beta, 6alpha, 12beta and 20 pro-S positions, in which the hydroxy group at position 6 has been converted to the corresponding alpha-L-rhamnopyranosyl-(1->2)-beta-D-glucopyranoside, and in which a double bond has been introduced at the 24-25 position.	2.17	1	12beta-hydroxy steroid; 20-hydroxy steroid; 3beta-hydroxy-4,4-dimethylsteroid; 3beta-hydroxy steroid; beta-D-glucoside; disaccharide derivative; ginsenoside; tetracyclic triterpenoid	anticoagulant; cardioprotective agent; plant metabolite
ginsenoside rh4 ginsenoside Rh4: isolated from Korean red ginseng Panax ginseng; structure in first source	8.02	4	triterpenoid saponin
(20R)-ginsenoside Rg3 (20R)-ginsenoside Rg3 : A ginsenoside found in Panax japonicus var. major that is dammarane which is substituted by hydroxy groups at the 3beta, 12beta and 20 pro-R positions, in which the hydroxy group at position 3 has been converted to the corresponding beta-D-glucopyranosyl-beta-D-glucopyranoside, and in which a double bond has been introduced at the 24-25 position.	2.17	1	ginsenoside; glycoside; tetracyclic triterpenoid	antioxidant; plant metabolite

Condition	Relationship Strength	Studies
Acute Confusional Senile Dementia [description not available]	2.6	1
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	3.01	2
Alzheimer Disease A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57)	2.6	1
Fatty Liver, Nonalcoholic [description not available]	2.6	1
Innate Inflammatory Response [description not available]	2.82	2
Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.	7.82	2
Non-alcoholic Fatty Liver Disease Fatty liver finding without excessive ALCOHOL CONSUMPTION.	2.6	1
Colitis Gravis [description not available]	2.25	1
Colitis, Ulcerative Inflammation of the COLON that is predominantly confined to the MUCOSA. Its major symptoms include DIARRHEA, rectal BLEEDING, the passage of MUCUS, and ABDOMINAL PAIN.	2.25	1
Disbacteriosis [description not available]	2.31	1
Acute Liver Injury, Drug-Induced [description not available]	2.31	1
Chemical and Drug Induced Liver Injury A spectrum of clinical liver diseases ranging from mild biochemical abnormalities to ACUTE LIVER FAILURE, caused by drugs, drug metabolites, herbal and dietary supplements and chemicals from the environment.	2.31	1
Hepatocellular Carcinoma [description not available]	7.31	1
Cancer of Liver [description not available]	2.31	1
Carcinoma, Hepatocellular A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.	2.31	1
Liver Neoplasms Tumors or cancer of the LIVER.	2.31	1
Carcinoma, Non-Small Cell Lung [description not available]	2.15	1
Cancer of Lung [description not available]	2.15	1
Carcinoma, Non-Small-Cell Lung A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.	2.15	1
Lung Neoplasms Tumors or cancer of the LUNG.	2.15	1
Anemia A reduction in the number of circulating ERYTHROCYTES or in the quantity of HEMOGLOBIN.	7.17	1
Alcoholic Liver Diseases [description not available]	2.21	1
Liver Diseases, Alcoholic Liver diseases associated with ALCOHOLISM. It usually refers to the coexistence of two or more subentities, i.e., ALCOHOLIC FATTY LIVER; ALCOHOLIC HEPATITIS; and ALCOHOLIC CIRRHOSIS.	2.21	1
Diabetes Mellitus, Adult-Onset [description not available]	2.21	1
Diabetes Mellitus, Type 2 A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.	2.21	1
Cancer of Esophagus [description not available]	2.21	1
Esophageal Neoplasms Tumors or cancer of the ESOPHAGUS.	2.21	1
Sensitivity and Specificity Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)	2.07	1

ginsenoside rk3

Description

Cross-References

Synonyms (11)

Research Excerpts

Overview

Pharmacokinetics

Bioavailability

Bioassays (2)

Research

Studies (16)

Market Indicators

Research Demand Index: 20.55

Study Types

ginsenoside rk3

Description

Cross-References

Synonyms (11)

Research Excerpts

Overview

Pharmacokinetics

Bioavailability

Bioassays (2)

Research

Studies (16)

Market Indicators

Research Demand Index: 20.55

Study Types

Related Drugs (15)

Related Conditions (28)